Bayesian ranking and selection methods using hierarchical mixture models in microarray studies

HISASHI NOMA
Department of Biostatistics, Kyoto University School of Public Health
Yoshida Konoe-cho, Sakyō-ku, Kyoto 606-8501, Japan

SHIGEYUKI MATSUI
Department of Data Science, The Institute of Statistical Mathematics
10-3 Midori-cho, Tachikawa, Tokyo 190-8562, Japan

TAKASHI OMORI, TOSIYA SATO
Department of Biostatistics, Kyoto University School of Public Health
Yoshida Konoe-cho, Sakyō-ku, Kyoto 606-8501, Japan

Correspondence: Hisashi Noma
Department of Biostatistics, Kyoto University School of Public Health
Yoshida Konoe-cho, Sakyō-ku, Kyoto 606-8501, Japan
Phone +81-75-753-9466
FAX +81-75-753-4487
e-mail: nomahi@bstat.mbox.media.kyoto-u.ac.jp

[Accepted for publication October 20, 2009]
Summary

The main purpose of microarray studies is screening to identify differentially expressed genes as candidates for further investigation. Because of limited resources in this stage, prioritizing or ranking genes is a relevant statistical task in microarray studies. In this article, we develop three empirical Bayes methods for gene ranking on the basis of differential expression, using hierarchical mixture models. These methods are based on (1) minimizing mean squared errors of estimation for parameters, (2) minimizing mean squared errors of estimation for ranks of parameters, and (3) maximizing sensitivity in selecting prespecified numbers of differential genes, with the largest effect. Our methods incorporate the mixture structures of differential and non-differential components in empirical Bayes models to allow information borrowing across differential genes, with separation from nuisance, non-differential genes. The accuracy of our ranking methods is compared with that of conventional methods through simulation studies. An application to a clinical study for breast cancer is provided.

Key words: empirical Bayes; gene expression; hierarchical mixture models; microarrays; ranking and selection.
1. Introduction

Recent developments in gene expression microarrays have enabled comprehensive screening of differentially expressed genes between different clinical subclasses. In genome-wide studies with microarrays, multiple testing is widely adopted, and statistically significant genes are reported as candidate genes for further investigation. Because of limited resources at this stage, prioritizing or ranking genes is needed.

There are at least two criteria on which genes are ranked; one is related to the probability of non-differential expression, the other is to the magnitude of differential expression or the strength of association with the clinical outcome. An example of the former criterion is the local false discovery rate, which represents the posterior probability of non-differential expression of each gene (Efron and others, 2001; Efron, 2008). A similar or related statistic using hierarchical Bayes models was derived and discussed by Newton and others (2004). The ranking based on the local false discovery rate is optimal for selecting differentially expressed genes from the viewpoint of Bayesian decision theory (Berger, 1985; McLachlan and others, 2006).

For the latter criterion regarding magnitude of association, the fold change—which corresponds to the ratio or difference of mean expression levels between different clinical subtype classes—is commonly used (McLachlan and others, 2004; Guo and others, 2006; Choe and others, 2005). Some authors have reported that gene ranking based on the fold change is reproducible (MAQC Consortium, 2006) and accurate for large absolute changes in gene expression (Witten and Tibshirani, in preparation¹). However, the accuracy of gene ranking can be improved by “borrowing strength” across genes. Specifically, the ranking of empirical Bayes estimators can be more accurate than that of


An important feature of microarray data is that a large proportion of the genes investigated are non-differential. The incorporation of this feature of microarray data could allow for information-sharing across differential genes separated from nuisance, non-differential genes. In this article, we propose empirical Bayes methods for gene ranking on the basis of the strength of association under structural models that reflect this feature. Specifically, we assume a hierarchical mixture model with a two-stage compound sampling model, in which the second stage of the model is a mixture distribution of differential and non-differential components (Newton and Kendziorski, 2003; Lönnstedt and Speed, 2002; Gottardo and others, 2003).

We present the framework of the hierarchical mixture modeling and its empirical Bayes inference in Section 2 and develop three ranking and selection rules in Section 3. In Section 4, we compare the proposed rules with conventional or other methods through simulations. We describe the application to a breast cancer clinical study in Section 5. Discussion is provided in Section 6.
2. Hierarchical mixture modeling

The gene expression data considered here comprise normalized log ratios from two-color cDNA arrays or normalized log signals from oligonucleotide arrays (e.g., Affymetrix GeneChip). We consider a two-class comparison problem: a binary response—e.g., a poor prognosis and good prognosis, is compared on the basis of the expression levels of $m$ candidate genes from $n$ samples. For gene $j$, let $\theta_j$ be the parameter of interest, i.e., the difference in the mean expression level between the two classes ($j = 1, \ldots, m$). As an estimator of $\theta_j$, let $Y_j$ be the fold change, which is the difference in the sample mean expression level obtained from $n$ samples (Guo and others, 2006; Choe and others, 2005).

We consider a two-stage model with i.i.d. sampling from a three-component mixture prior and from a normal gene-specific sampling model:

\[
Y_j \mid \theta_j \sim N(\theta_j, \sigma_j^2) \tag{2.1}
\]

\[
\theta_j \sim \pi_0 \delta(\theta) + \pi_1 g_1(\theta \mid \xi_1) + \pi_2 g_2(\theta \mid \xi_2).
\]

Here, $\delta(\theta)$ is the Dirac delta function, representing non-differential expression between two classes. The density functions $g_1(\theta \mid \xi_1)$ and $g_2(\theta \mid \xi_2)$ correspond to the non-null components of under-expression and over-expression, respectively, for a particular class, e.g., poor prognosis. The proportion $\pi_i$ represents the mixing proportion ($i = 0, 1, 2$), with $\pi_0 + \pi_1 + \pi_2 = 1$. In the first-stage model in (2.1), we assume that the gene-specific variance $\sigma_j^2$ is known. We denote $Z_{ij}(i = 0,1,2; j = 1,2,\ldots,m)$ as unobservable indicator random variables, such that $Z_{ij} = 1$ if gene $j$ belongs to the $i$-th component, and $Z_{ij} = 0$ otherwise. The $\pi_i$ ($i = 0,1,2$) correspond to the probability of $Z_{ij} = 1$. An estimate of the hyperparameter $\eta = (\pi_0, \pi_1, \xi_1, \xi_2)$ can be obtained by maximizing the marginal likelihood of $Y_j$ (Carlin and Louis, 2000). We employ the expectation maximization (EM) algorithm.
(Dempster and others, 1977) to cope with the unobservable indicator variable $Z_{ij}$ in the mixture model. The hyperparameters of interest, i.e., $\xi_1$ and $\xi_2$ in the distribution of the effect sizes $\theta_j$, can be estimated more stably by using fixed or, more generally, constrained estimates of the mixing proportions or by introducing prior distributions on the mixing proportions in the EM algorithm (e.g., Gottardo and others, 2003; Newton and others, 2001; Newton and others, 2004; Lo and Gottardo, 2007). In this article, we consider the former strategy and adopt a two-stage procedure that estimates $\pi_0$ as in Storey (2002) and treat this estimate as a fixed value in the EM algorithm. We assume conjugate normal distributions $N(\mu_1, \tau_1^2)$ and $N(\mu_2, \tau_2^2)$ ($\mu_1 > 0, \mu_2 < 0$) for $g_1(\theta | \xi_1)$ and $g_2(\theta | \xi_2)$, respectively.

3. Posterior inference

For simplicity, our discussion here is restricted to identifying genes with the greatest positive $\theta_j$, i.e., overexpressed genes for a particular class. Its extension to the two-sided version—to obtain genes with the greatest absolute $\theta_j$ for both over-expressed and under-expressed genes—is straightforward.

3.1. Ranking based on posterior mean (PM)

From model (2.1), we obtain the posterior distribution:

$$p_j(\theta | y_j) = \Pr(Z_{0j} = 1 | y_j) p_{0j}(\theta | y_j) + \Pr(Z_{1j} = 1 | y_j) p_{1j}(\theta | y_j) + \Pr(Z_{2j} = 1 | y_j) p_{2j}(\theta | y_j),$$

where $p_{0j}$, $p_{1j}$, and $p_{2j}$ are the posterior densities of each component, which are obtained as $\delta(\theta)$ and
respectively. The posterior probability that gene $j$ belongs to the $i$-th component ($i = 0,1,2$) is

$$Pr(Z_{ij} = 1|y_j) = \frac{\pi_i h_{ij}(y_j | \xi_i)}{\pi_0 h_{0j}(y_j) + \pi_1 h_{1j}(y_j | \xi_1) + \pi_2 h_{2j}(y_j | \xi_2)}.$$  \hfill (3.1)

Here, $h_{0j}, h_{1j},$ and $h_{2j}$ are the marginal densities of the $Y_j$s, in each component, namely $N(0, \sigma_j^2), N(\mu_1, \sigma_j^2 + \tau_1^2)$, and $N(\mu_2, \sigma_j^2 + \tau_2^2)$ for $i = 0,1,2$, respectively.

Minimizing the squared error loss, the Bayes estimator of $\theta_j$ is the posterior mean (Carlin and Louis, 2000). For the hierarchical mixture model, the posterior mean is obtained as

$$E[\theta_j|Y_j] = Pr(Z_{0j} = 1|y_j) E[\theta_j|Z_{0j} = 1,Y_j] + Pr(Z_{1j} = 1|y_j) E[\theta_j|Z_{1j} = 1,Y_j]$$

$$+ Pr(Z_{2j} = 1|y_j) E[\theta_j|Z_{2j} = 1,Y_j].$$  \hfill (3.2)

This is the weighted average of the posterior means of each component, where the weights are the posterior probabilities of component membership (3.1). The ranking is thus obtained via the magnitude of the posterior means (the ‘PM’ method).

### 3.2. Ranking based on rank posterior means (RPM)

If the ranks of the parameters are the target feature, using the rank estimator is more appropriate than using the parameter estimator (Laird and Louis, 1989; Shen and Louis, 1998; Louis and Shen, 1999). We consider ranking within differential genes with positive effects, defined as

$$R_j = Z_{ij} \sum_{k=1}^{m} Z_{ik} I(\theta_j \geq \theta_k),$$
where $R_j$ has a large value when gene $j$ belongs to the non-null component with positive effect and has a large $\theta_j$ value, or is 0 when gene $j$ belongs to the other components. For the squared error loss, the Bayes estimator of $R_j$ is the posterior mean:

$$E[R_j \mid y_j] = \Pr(Z_{1j} = 1 \mid y_j) \sum_{k=1}^m \Pr(Z_{1k} = 1 \mid y_j) \Pr(\theta_j \geq \theta_k \mid y_j, y_k) \; .$$

(3.3)

Thus, gene ranking is obtained by the rank posterior means (the ‘RPM’ method).

### 3.3. Ranking based on tail-area posterior probability (TPP)

Because of the limited resources available in subsequent studies, the number of selected genes may be prespecified as a small number, $K$ (Matsui and others, 2008). In this situation, we consider the $K$ genes with the greatest positive effects as the target. Lin and others (2006) provided various loss functions and derived optimal ranking and selection rules via Bayesian decision theory; we generalize their rank-based misclassification loss function that equivalently penalizes to misclassifications between the true top $K$ ranked genes and other the differential genes:

$$L_{0/1}(K, R, R^{est}) = \frac{1}{m} \sum_{j=1}^m \left\{ FP(K, R_j, R_j^{est}) + FN(K, R_j, R_j^{est}) \right\} \; ,$$

where

$$FP(K, R_j, R_j^{est}) = I\{R_j \leq m_1 - K, R_j^{est} > m_1 - K\}$$

$$FN(K, R_j, R_j^{est}) = I\{R_j > m_1 - K, R_j^{est} \leq m_1 - K\} \; .$$

The $R_j^{est}$ are estimators of the $R_j$, and $m_1 = \sum_i Z_{ij}$ is the number of genes generated from the non-null component with positive effects in the $m$ measured genes.

The derived optimal rule is to select $K$ genes which have large values of

$$\tilde{P}_j(K) = \Pr(R_j > (m_1 - K) \mid y) \; ,$$
as in Lin and others (2006). However, it is difficult to obtain the posterior distribution of \( R_j \) and to calculate \( \tilde{P}_j(K) \) directly. Instead, we can use a simple computable approximation of \( \tilde{P}_j(K) \). Define \( \gamma = K / (m_1+1) \) and let \( G_1 \) be the cumulative distribution function of \( g_1 \). Under the similar conditions of Theorem 5 described in Lin and others (2006), the approximation of \( \tilde{P}_j(K) \) is obtained as

\[
P^*_{j}(K) = \Pr(\theta_j \geq G_1^{-1}(\gamma) \mid Z_{ij} = 1, y) \Pr(Z_{1j} = 1 \mid y),
\]

where

\[
\bar{G}_1(t) = \frac{\sum_{j=1}^{m} \Pr(\theta_j \leq t \mid z_{ij} = 1, y_j) \Pr(Z_{1j} = 1 \mid y_j)}{\sum_{j=1}^{m} \Pr(Z_{1j} = 1 \mid y_j)}.
\]

\( P^*_{j}(K) \) corresponds to the tail-area posterior probability of \( \theta_j \). Proof of this approximation is provided in the Supplementary Material. Here, we denote this rule as the ‘TPP (tail-area posterior probability’ method. The quantity \( m_1 \) can be replaced by its estimator \( \sum_j \Pr(Z_{1j} = 1 \mid y_j) \) (McLachlan and others, 2004).

4. Simulation studies

We conducted a series of simulation studies to assess the performance of our proposed methods. Details of the simulations are presented in Section A of the Supplementary Material available at Biostatistics online.

In summary, the sensitivity and root mean squared error (RMSE) of all the proposed methods were better than those of the other methods. As was expected, the TPP method had the greatest sensitivity, the RPM method had the lowest RMSE values, and the posterior probability of differentially expressed (PPDE) (3.1) ranking had the lowest false
positive rate. The posterior mean under unimodal hierarchical model (PM$_U$) method, which lacks mixture components, had a lower sensitivity and a larger RMSE, compared with the PM method. The fold change had comparable sensitivity and RMSE values for large sample sizes, but not for small sample sizes. The fold change had very large false positive rates even when the sample size was large, because it does not guard against selecting null genes.

5. Application to a breast cancer study

We illustrate the proposed methods using the dataset from a breast cancer clinical study (Wang and others, 2005). The data are available from the NCBI GEO database (GSE2034). This study was a large Affymetrix-based gene expression profiling study of 286 untreated patients with lymph-node-negative primary breast cancer, and analyzed estrogen receptor positive and negative patients separately. Here, we restrict our attention to the estrogen receptor positive patients. In this study, out of 22,283 genes, 60 genes were selected on the basis of statistical significance for predicting the risk of relapse. We considered comparison of patients who were relapse-free at five years (good prognostic group) and the other patients (poor prognostic group). During the follow-up period, of the 204 estrogen receptor positive patients, 138 patients were relapse-free at five years, whilst 66 developed distant metastasis.

The hyperparameters were estimated as $\hat{\pi}_0 = 0.769$, $\hat{\pi}_1 = 0.055$, $\hat{\pi}_2 = 0.176$, $\hat{\mu}_1 = 0.182$, $\hat{\sigma}_1^2 = 0.021^2$, $\hat{\mu}_2 = -0.149$, $\hat{\sigma}_2^2 = 0.014^2$. The $\sigma_j^2$ were estimated on a gene-by-gene basis assuming a common variance between the two prognostic groups. Figure 1 represents comparison between the RPM statistic, which was shown to yield...
good gene ranking in the simulation studies in Section 4, and the other statistics for overexpressed genes in the poor prognostic group. Similar trends were observed in underexpressed genes for the poor prognostic group. Figure 1(a) indicates substantial discrepancy in gene ranking between the RPM statistic and the fold change. In Figure 1(b), top ranked genes based on the RPM statistics had the smallest $P$-values, but low-ranked genes using the RPM statistic could also have very small $P$-values. Figures 1(c) and (d) indicate good agreement of gene ranking among the PM, RPM, and TPP statistics, especially, for the greatest values of these statistics (i.e., for top-ranked genes). For example, out of top 30 genes based on the RPM statistic, 27 and 21 genes were also selected in top 30 genes based on the PM and TPP statistics, respectively. The discrepancy in gene ranking between the proposed methods and fold change in Figure 1(a) would reflect very high false positive rates for fold change as we found in our simulation study.

We also investigated overlap of top genes between the proposed methods and the 60 genes reported in the original paper (see Section B of the Supplementary Material at Biostatistics online). There were 7 overlaps when the top 30 genes were selected by the RPM method for each of overexpression and underexpression in the poor prognostic group. 26 (43%) of the 60 genes reported in the original paper were amongst the top 1% of genes according to their RPM values. As indicated by Figure 1(b), there were fewer overlaps between the proposed methods and the $t$-statistic. Because the sensitivity of the proposed methods was higher, gene ranking based on the proposed methods would be more reliable.
6. Discussion

In microarray studies, prioritizing or ranking genes is an important statistical task. Because the number of simultaneous comparisons can go into the tens of thousands, gene ranking can suffer from a lack of accuracy. Sharing information across genes and incorporating the null/non-null mixture structure are expected to be effective in improving accuracy. As seen in our simulations, the proposed PM, RPM, and TPP methods showed higher sensitivity and lower error of rank estimation for differential genes with the greatest effects, compared to conventional methods. In addition, these methods had low false positive rates. Although the results of our resampling studies indicated that such good performance can be compromised by violating the model assumptions, including independence among genes and the normality of gene expressions, our ranking methods, especially the RPM method, were still accurate compared to the other methods. Violation of normality can be handled by using other parametric distributions, as noted in Section 2. The greater accuracy of the PM method, compared to the PM\textsubscript{U} method, shows that incorporating the null-mixture component is effective in improving ranking accuracy. The PPDE ranking had the lowest false positive rate, as was expected because of its theoretical optimality (Berger, 1985; McLachlan and others, 2006). These results are reasonable because a ranking method performs well for the criterion or loss function in gene ranking from which it is derived. Ranking methods should be selected according to the criterion of interest in gene ranking, i.e., depending on the probability of non-differential expression or the magnitude of differential expression.

The ranking accuracy of fold change would be asymptotically optimal because of the
good performance in sensitivity and RMSE of gene ranking under large sample scenarios \((n/2 = 80)\) in the simulations described in the Supplementary Material. Further, the RMSE of fold change was lower than the proposed empirical Bayes methods under large sample scenarios in the resampling exercise in the Supplementary Material. A similarly good performance using conventional methods, compared to those of empirical Bayes methods, has also been seen with large samples in other experiments (Greenland, 1993). In small sample scenarios, however, optimality was largely violated. Further, with respect to false positive rates, the ranking of the fold change did not perform well, even with large samples. Although the MAQC project (MAQC Consortium, 2006) reported good reproducibility of ranking based on fold change, “accuracy” and “reproducibility” are different concepts as remarked by Witten and Tibshirani (in preparation). Hence, ranking via the fold change is not recommended for general use when the objective is to prevent false positive detection.

For general practical use, the proposed three methods should be used according to the purpose of analysis. However, for the three proposed methods, the sensitivities in detecting differential genes with the greatest effects as well as the false positive rates were comparable. Accordingly, we would recommend the RPM method.

As noted in Section 2, attempts to obtain stable estimates of the hyperparameters of interest, i.e., \(\xi_1\) and \(\xi_2\) in the distribution of the effect sizes \(\theta_j\), include the use of reasonable estimates of the mixing proportions such as treating \(\pi_0\) as fixed quantities, invoking reasonable constraints or placing prior distributions on the mixing proportions in the EM algorithm. Comparison of these approaches is outside the scope of this paper, but it is an important subject for future research.
The R code for gene ranking is available in the Supplementary Material at *Biostatistics* online.

**Supplementary Material**

Supplementary material is available at http://biostatistics.oxfordjournals.org.

**Acknowledgements**

The authors would like to thank Tomonori Oura for many valuable comments and advice on an earlier draft of this article, and the editor for helpful comments and suggestions.

*Conflict of Interest*: None declared.
References


Figure 1. Comparison of the RPM statistic with other statistics for the breast cancer dataset. The four panels show scatter plots of the RPM statistic versus the fold change (a), the $P$-values from two-sample $t$-tests (b), the PM statistic (c), and the TPP statistic with $K = 30$, for overexpressed genes in the poor prognostic group.